Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Table 3 Responder status for primary PRO measures from baseline to week 24 of the ATLAS study

	Placebo (n = 107) n (%)	Adalimumab 40 mg every other week (n = 208) n (%)	P value^a
SF-36 PCS, 0–50
Responder, ≥ 3-point reduction	41 (39.8)	138 (67.0)	< 0.001
BASFI, 0–10
Responder, ≥ 21% reduction	38 (35.5)	142 (68.6)	< 0.001
ASQOL, 0–18
Responder, ≥ 1.8-point reduction	46 (43.0)	135 (64.9)	< 0.001

^aP-values based on chi-square test.
ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASFI = Bath AS Functional Index; PCS = Physical Component Summary; PRO = patient-reported outcome; SF-36 = Short Form-36 Health Survey.

ISSN: 1478-6362